We are committed to finding a safe, effective, and patient-friendly therapy for food and pediatric allergy patients

 

OLFUS-VIPES Results

Latest News

Monthly information regarding the total number of voting rights and total number of shares of the Company 

DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age 

Documentation

20F- Form 2016

Agenda

Citi’s 12th Annual Biotech Conference

Boston, MA, USA